Coherus BioSciences Revenue and Competitors



Total Funding



Estimated Revenue & Valuation

  • Coherus BioSciences's estimated annual revenue is currently $22.8M per year.(i)
  • Coherus BioSciences received $75.0M in venture funding in January 2019.
  • Coherus BioSciences's estimated revenue per employee is $66,818
  • Coherus BioSciences's total funding is $477.5M.

Employee Data

  • Coherus BioSciences has 341 Employees.(i)
  • Coherus BioSciences grew their employee count by -11% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
Add Company

Coherus BioSciences is the leading biologics platform company solely focused on delivering high-quality biosimilar therapeutics that will expand patient access to life-changing medicines in regulated markets worldwide. Founded in 2010, Coherus is a late-stage biologics platform company focused on the global biosimilar market. Headquartered in the San Francisco Bay Area and composed of a team of industry veterans with decades of experience in pioneering biologics companies, our goal is to become a global leader in the biosimilar market by leveraging our team's collective expertise in key areas such as process science, analytical characterization, protein production and clinical-regulatory development. Our commercialization partnerships include global pharmaceutical companies in Europe, Asia and Latin America. Biosimilars are intended for use in place of existing, branded biologics to treat a range of chronic and often life-threatening diseases, with the potential to reduce costs and expand patient access. For additional information, please visit If you are interested in joining a highly innovative and exciting company, please visit our careers webpage at for a list of career opportunities.

keywords:Biotechnology,Cleantech,Healthcare,Pharmaceuticals,Wind Power


Total Funding


Number of Employees


Revenue (est)


Employee Growth %





Coherus BioSciences News

2022-04-20 - Caliber Associates Recruits Chief Medical Officer for Coherus ...

... chief medical officer of Coherus BioSciences in Redwood City, CA. ... the leadership team of Coherus with his deep clinical development...

2022-04-19 - Coherus BioSciences, Inc. (NASDAQ:CHRS) Expected to ...

Coherus BioSciences, Inc. (NASDAQ:CHRS) Expected to Announce Quarterly Sales of $71.08 Million. Posted by admin on Apr 27th, 2022.

2022-04-17 - Coherus BioSciences, Inc. (NASDAQ:CHRS) Given ...

Coherus BioSciences, Inc. (NASDAQ:CHRS) Given Consensus Rating of “Buy” by Brokerages. Posted by admin on Apr 26th, 2022.

2019-09-08 - Coherus Biosciences (NASDAQ:CHRS) Downgraded by ...

BidaskClub cut shares of Coherus Biosciences (NASDAQ:CHRS) from a buy rating to a hold rating in a report released on Friday, BidAskClub ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding

Coherus BioSciences Funding

DateAmountRoundLead InvestorsReference
2014-11-07$85.0MUndisclosedJ.P. Morgan Securities LLCArticle
2015-03-31$115.0MUndisclosedJ.P. Morgan Securities LLCArticle
2015-04-02$138.0MUndisclosedJ.P. Morgan Securities LLCArticle
2017-02-09$143.8MUndisclosedJ.P. MorganArticle
2019-01-08$75.0MUndisclosedHealthcare Royalty PartnersArticle